Hepatitis C in Developing Countries
Current and Future Challenges
Nonfiction, Science & Nature, Science, Biological Sciences, Microbiology, Health & Well Being, Medical
| Author: | ISBN: | 9780128032343 | |
| Publisher: | Elsevier Science | Publication: | November 23, 2017 |
| Imprint: | Academic Press | Language: | English |
| Author: | |
| ISBN: | 9780128032343 |
| Publisher: | Elsevier Science |
| Publication: | November 23, 2017 |
| Imprint: | Academic Press |
| Language: | English |
Hepatitis C in Developing Countries: Current and Future Challenges explores the current state of HCV in several countries, including Africa, Asia and South America. It maintains a dedicated focus on the epidemiology, clinical patterns, virologic diversity, coinfections, natural history and progression, complications, and response to standard of care (SOC) pegylated interferon and ribavirin therapy of HCV with recommendations specific to middle and low income countries. Readers will find detailed information on the burden of HCV infection from a global health and economic perspective, along with data from multicenter trials on DAAs that have enrolled patients infected with HCV non-genotype 1.
- Features coverage on the prevention of, or inhibition of, liver fibrosis, cirrhosis, and hepatocellular carcinoma
- Presents data from trials on patients with diverse ethnic backgrounds and those infected with genotypes 3, 4, 5, 6
- Addresses the epidemiology, modes of transmission, socio-political aspects, genotypes, and co-infections of Hepatitis C
Hepatitis C in Developing Countries: Current and Future Challenges explores the current state of HCV in several countries, including Africa, Asia and South America. It maintains a dedicated focus on the epidemiology, clinical patterns, virologic diversity, coinfections, natural history and progression, complications, and response to standard of care (SOC) pegylated interferon and ribavirin therapy of HCV with recommendations specific to middle and low income countries. Readers will find detailed information on the burden of HCV infection from a global health and economic perspective, along with data from multicenter trials on DAAs that have enrolled patients infected with HCV non-genotype 1.
- Features coverage on the prevention of, or inhibition of, liver fibrosis, cirrhosis, and hepatocellular carcinoma
- Presents data from trials on patients with diverse ethnic backgrounds and those infected with genotypes 3, 4, 5, 6
- Addresses the epidemiology, modes of transmission, socio-political aspects, genotypes, and co-infections of Hepatitis C
